No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
181 |
4. Check minimum number of eventsNone |
181 |
5. Include endpointsNone |
181 |
6. Filter based on genotype QC (FinnGen only) |
177 |
Control definitions (FinnGen only)
- Control exclude
- Q17_OTHER_CONGEN_MALFO_DIGES_SYSTEM1
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- Q3[8-9]|Q4[0-5]
- Name in latin
- Malformationes congenitae oesophagi
Similar endpoints
↥List of similar endpoints to
Congenital malformations of oesophagus
based on the number of shared cases.
Similar with more cases:
- Other congenital malformations of the digestive system
- Other congenital malformations of the digestive system, including avohilmo
- Congenital malformations, deformations and chromosomal abnormalities
- Congenital malformations, deformations and chromosomal abnormalities, including avohilmo
- Any operation in hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1406 | 640 | 758 |
| Only index persons | 1057 | 489 | 568 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 21.73 | 34.07 | 10.71 |
| Only index persons | 35.77 | 49.40 | 24.03 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 177 | 78 | 99 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 61.11 | 57.92 | 63.62 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 181
- Matched controls
- 1810
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q39.6
ICD-10 Finland
Diverticulum of oesophagus
+∞
105.9
91
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
12.2
62.1
130
313
K22.5
ICD-10 Finland
Diverticulum of oesophagus, acquired
131.6
39.6
41
*
R13
ICD-10 Finland
Dysphagia
10.0
39.2
53
72
Q39.11
ICD-10 Finland
Atresia of oesophagus with broncho-oesophageal fistula
+∞
36.7
34
*
JC2AB
NOMESCO Finland
Oesophagus X-ray examination with contrast
66.7
29.3
33
6
JCA55
NOMESCO Finland
Endoscopic dilatation of oesophagus
77.1
29.0
32
5
UGC02
NOMESCO Finland
Rigid bronchoscopy
114.4
27.5
29
*
Q39.0
ICD-10 Finland
Atresia of oesophagus without fistula
+∞
22.3
21
*
Q39.10
ICD-10 Finland
Atresia of oesophagus with broncho-oesophageal fistula
+∞
21.3
20
*
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
5.9
18.8
39
81
UJD02
NOMESCO Finland
Gastroscopy
8.4
17.9
25
34
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.0
17.5
35
70
75020
ICD-8 Finland
Other congenital anomalies of upper alimentary tract, Atresia oesophagi
+∞
15.9
15
*
UJC12
NOMESCO Finland
Flexible oesophagoscopy
49.7
15.4
18
*
Q39.19
ICD-10 Finland
Atresia of oesophagus with tracheo/broncho-oesophageal fistula
+∞
14.8
14
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.5
14.7
74
298
ZXD10
NOMESCO Finland
Scheduled procedure
3.3
14.4
95
450
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
37.3
13.8
17
5
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
4.8
13.8
35
86
Q39.9
ICD-10 Finland
Congenital malformation of oesophagus, unspecified
+∞
13.7
13
*
JCA60
NOMESCO Finland
Transcervical excision of diverticulum of oesophagus
150.8
13.6
14
*
Q39.3
ICD-10 Finland
Congenital stenosis and stricture of oesophagus
+∞
12.6
12
*
Q39.88
ICD-10 Finland
Other congenital malformations of oesophagus
+∞
12.6
12
*
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
29.0
12.3
16
6
A02BC05
ATC
esomeprazole; systemic
3.0
11.7
86
422
A03FA02
ATC
cisapride; oral, rectal
5.0
11.6
27
61
7503C
ICD-9 Finland
Other congenital anomalies of upper alimentary tract, Tracheooesophageal fistula, oesophageal atresia and stenosis[RUOKATORVIATRESIA ALAFISTELEINEEN]
+∞
11.6
11
*
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
5.0
11.1
26
59
1300
FHL
Esophagogastroduodenoscopy (also includes staining)
46.3
11.1
13
*
JD1EE
NOMESCO Finland
Ultrasound examination of gastro-oesophageal reflux
116.5
10.5
11
*
JCE31
NOMESCO Finland
Treatment esophageal atresia
+∞
10.5
10
*
WX402
NOMESCO Finland
General anaesthesia
2.9
9.8
62
276
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
9.4
103
602
ZXE00
NOMESCO Finland
One hour or less
2.6
9.3
90
495
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
9.1
73
366
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
9.4
9.0
18
21
UJC02
NOMESCO Finland
Rigid oesophagoscopy
25.5
9.0
12
5
Z2221
NOMESCO Finland
Medical doctor
2.7
8.9
66
317
A02BC01
ATC
omeprazole; systemic
2.7
8.7
63
299
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.8
8.6
54
237
K22.2
ICD-10 Finland
Oesophageal obstruction
21.3
8.6
12
6
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
8.6
78
413
XG413
NOMESCO Finland
Spirometry with oscillometry
13.7
8.5
14
11
1323
FHL
Esophagoscopy and dilatation
94.3
8.5
9
*
7503A
ICD-9 Finland
Other congenital anomalies of upper alimentary tract, Tracheooesophageal fistula, oesophageal atresia and stenosis[RUOKATORVIATRESIA ILMAN FISTELIÄ]
+∞
8.4
8
*
GD1RA
NOMESCO Finland
Dynamic X-ray examination of respiratory organs with convetional X-ray picture
+∞
8.4
8
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
18.2
8.2
12
7
T18.1
ICD-10 Finland
Foreign body in oesophagus
18.2
8.2
12
7
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.2
8.1
23
61
R4110
NOMESCO Finland
Physiotherapy
2.6
7.9
65
326
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
7.8
49
214
TJD20
NOMESCO Finland
Change of gastrostomy tube
19.4
7.7
11
6
J45.1
ICD-10 Finland
Nonallergic asthma
3.5
7.6
28
89
ZXD20
NOMESCO Finland
Day surgery
3.3
7.4
30
102
1310
FHL
Esophagogastroscopy
+∞
7.3
7
*
K22.8
ICD-10 Finland
Other specified diseases of oesophagus
+∞
7.3
7
*
1304
FHL
Esophagogastroduodenoscopy and other therapeutic procedure
+∞
7.3
7
*
Q39.80
ICD-10 Finland
Duplication of oesophagus
+∞
7.3
7
*
ZXD05
NOMESCO Finland
Urgent procedure
2.4
7.2
70
376
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.6
7.2
50
230
Z3226
NOMESCO Finland
Physiotherapist
2.6
7.2
50
230
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
7.0
30
105
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.0
6.9
20
54
R03DC03
ATC
montelukast; oral
2.8
6.8
40
168
XJC02
NOMESCO Finland
Mesurement of oesophageal pressure and pressure profile of lower oesophageal sphincter
41.7
6.8
8
*
JCA08
NOMESCO Finland
Endoscopic removal of foreign body from oesophagus
23.5
6.7
9
*
Z3229
NOMESCO Finland
Other healthcare associate professional
3.2
6.7
28
97
JBC00
NOMESCO Finland
Gastro-oesophageal antireflux operation
72.3
6.5
7
*
JDB00
NOMESCO Finland
Gastrostomy
72.3
6.5
7
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.7
6.3
40
174
Q87.26
ICD-10 Finland
VATER association
+∞
6.3
6
*
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
OMOP4822009 [45756830]
1.6e+00
2.1e+00
—
1.0e+50
1.0e+50
3.8e+00
2.2e+00
cases:7.14%
controls:1.49%
cases:4.55%
controls:0.58%
—
—
cases:11.04%
controls:0.00%
cases:5.19%
controls:0.00%
cases:17.45%
controls:0.47%
cases:9.84%
controls:1.23%
11
23
143
1517
7
9
147
1531
—
17
0
137
1540
8
0
146
1537
26
7
123
1483
12
15
110
1202
Outpatient Visit
OP [9202]
OP [9202]
3.3e-01
7.1e-01
6.1e-01
5.5e+00
7.7e-01
1.0e+00
9.4e-01
cases:75.32%
controls:68.70%
cases:70.78%
controls:54.42%
cases:17.53%
controls:10.39%
cases:43.51%
controls:0.32%
cases:21.43%
controls:11.19%
cases:75.17%
controls:51.48%
cases:90.16%
controls:78.14%
116
1058
38
482
109
838
45
702
27
160
127
1380
67
5
87
1535
33
172
121
1365
112
767
37
723
110
951
12
266
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
1.5e+00
2.2e+00
1.0e+50
1.0e+50
1.0e+50
2.9e+00
1.3e+00
cases:17.53%
controls:4.35%
cases:10.39%
controls:1.23%
cases:3.25%
controls:0.00%
cases:24.03%
controls:0.00%
cases:4.55%
controls:0.00%
cases:18.12%
controls:1.21%
cases:13.93%
controls:4.27%
27
67
127
1473
16
19
138
1521
5
0
149
1540
37
0
117
1540
7
0
147
1537
27
18
122
1472
17
52
105
1165
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
1.1e+00
9.2e-01
2.0e+00
1.0e+50
2.1e+00
2.0e+00
7.3e-01
cases:24.03%
controls:9.35%
cases:9.09%
controls:3.83%
cases:4.55%
controls:0.65%
cases:12.34%
controls:0.00%
cases:5.19%
controls:0.65%
cases:18.12%
controls:2.95%
cases:18.03%
controls:9.61%
37
144
117
1396
14
59
140
1481
7
10
147
1530
19
0
135
1540
8
10
146
1527
27
44
122
1446
22
117
100
1100
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
9.2e-01
1.2e+00
1.6e+00
—
2.5e+00
1.4e+00
9.1e-01
cases:17.53%
controls:7.79%
cases:12.34%
controls:4.22%
cases:4.55%
controls:0.97%
—
—
cases:6.49%
controls:0.59%
cases:15.44%
controls:4.23%
cases:17.21%
controls:7.72%
27
120
127
1420
19
65
135
1475
7
15
147
1525
—
10
9
144
1528
23
63
126
1427
21
94
101
1123
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
8.1e-01
1.4e+00
2.8e+00
—
—
1.8e+00
6.6e-01
cases:13.64%
controls:6.56%
cases:10.39%
controls:2.73%
cases:5.19%
controls:0.32%
—
—
—
—
cases:11.41%
controls:2.15%
cases:12.30%
controls:6.74%
21
101
133
1439
16
42
138
1498
8
5
146
1535
—
—
17
32
132
1458
15
82
107
1135
Otolaryngology
4 [38004449]
4 [38004449]
4.9e-01
1.8e+00
1.6e+00
1.0e+50
2.7e+00
1.4e+00
5.6e-01
cases:18.18%
controls:12.01%
cases:17.53%
controls:3.38%
cases:3.90%
controls:0.78%
cases:14.29%
controls:0.00%
cases:4.55%
controls:0.33%
cases:14.09%
controls:3.89%
cases:18.85%
controls:11.67%
28
185
126
1355
27
52
127
1488
6
12
148
1528
22
0
132
1540
7
5
147
1532
21
58
128
1432
23
142
99
1075
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.5e-01
3.0e-01
1.1e+00
3.9e+00
7.1e-01
4.1e-01
5.1e-02
cases:46.10%
controls:42.47%
cases:48.05%
controls:40.71%
cases:31.82%
controls:12.92%
cases:22.73%
controls:0.58%
cases:24.68%
controls:13.86%
cases:52.35%
controls:42.08%
cases:54.92%
controls:53.66%
71
654
83
886
74
627
80
913
49
199
105
1341
35
9
119
1531
38
213
116
1324
78
627
71
863
67
653
55
564
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-2.2e-01
1.2e-01
—
—
—
3.5e+00
2.3e+00
cases:20.78%
controls:24.68%
cases:9.09%
controls:8.18%
—
—
—
—
—
—
cases:11.41%
controls:0.40%
cases:14.75%
controls:1.73%
32
380
122
1160
14
126
140
1414
—
—
—
17
6
132
1484
18
21
104
1196
Stomach Pathology biopsy report
66114-0 [40768797]
66114-0 [40768797]
1.2e+00
2.2e+00
—
1.0e+50
—
1.5e+00
1.6e+00
cases:9.09%
controls:2.79%
cases:7.79%
controls:0.91%
—
—
cases:12.99%
controls:0.00%
—
—
cases:4.70%
controls:1.07%
cases:9.84%
controls:2.22%
14
43
140
1497
12
14
142
1526
—
20
0
134
1540
—
7
16
142
1474
12
27
110
1190
Dysphagia
R13 [45573013]
R13 [45573013]
2.9e+00
—
—
1.0e+50
1.0e+50
—
2.1e+00
cases:9.74%
controls:0.58%
—
—
—
—
cases:3.25%
controls:0.00%
cases:3.25%
controls:0.00%
—
—
cases:7.38%
controls:0.99%
15
9
139
1531
—
—
5
0
149
1540
5
0
149
1537
—
9
12
113
1205
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
7.8e-01
9.3e-01
1.6e+00
—
1.3e+00
1.5e+00
6.5e-01
cases:21.43%
controls:11.10%
cases:16.23%
controls:7.08%
cases:9.74%
controls:2.08%
—
—
cases:7.14%
controls:2.15%
cases:20.81%
controls:5.64%
cases:22.13%
controls:12.90%
33
171
121
1369
25
109
129
1431
15
32
139
1508
—
11
33
143
1504
31
84
118
1406
27
157
95
1060
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
1.3e+00
7.9e-01
—
1.0e+50
—
1.7e+00
1.7e+00
cases:16.88%
controls:5.32%
cases:3.25%
controls:1.49%
—
—
cases:4.55%
controls:0.00%
—
—
cases:6.71%
controls:1.28%
cases:13.11%
controls:2.79%
26
82
128
1458
5
23
149
1517
—
7
0
147
1540
—
10
19
139
1471
16
34
106
1183
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.4e+00
—
—
—
—
1.9e+00
1.2e+00
cases:16.23%
controls:4.61%
—
—
—
—
—
—
—
—
cases:7.38%
controls:1.21%
cases:12.30%
controls:4.03%
25
71
129
1469
—
—
—
—
11
18
138
1472
15
49
107
1168
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-1.6e-02
1.4e-01
6.0e-01
3.7e+00
4.6e-01
1.2e-01
-9.4e-02
cases:61.04%
controls:61.43%
cases:58.44%
controls:55.13%
cases:35.71%
controls:23.31%
cases:38.96%
controls:1.49%
cases:33.77%
controls:24.40%
cases:58.39%
controls:55.44%
cases:66.39%
controls:68.45%
94
946
60
594
90
849
64
691
55
359
99
1181
60
23
94
1517
52
375
102
1162
87
826
62
664
81
833
41
384
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
7.0e-01
7.8e-01
1.6e-01
—
1.1e+00
8.7e-01
7.4e-01
cases:31.17%
controls:18.38%
cases:23.38%
controls:12.27%
cases:3.25%
controls:2.79%
—
—
cases:8.44%
controls:2.86%
cases:23.49%
controls:11.41%
cases:34.43%
controls:20.05%
48
283
106
1257
36
189
118
1351
5
43
149
1497
—
13
44
141
1493
35
170
114
1320
42
244
80
973
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
K21.0 [45543296]
2.1e+00
—
—
1.0e+50
—
—
1.9e+00
cases:4.55%
controls:0.58%
—
—
—
—
cases:3.90%
controls:0.00%
—
—
—
—
cases:6.56%
controls:0.99%
7
9
147
1531
—
—
6
0
148
1540
—
—
8
12
114
1205
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
113016006 [4010399]
—
2.2e+00
—
—
—
1.7e+00
1.7e+00
—
—
cases:5.84%
controls:0.65%
—
—
—
—
—
—
cases:3.36%
controls:0.60%
cases:8.20%
controls:1.56%
—
9
10
145
1530
—
—
—
5
9
144
1481
10
19
112
1198
FEV1
20150-9 [3024653]
20150-9 [3024653]
8.4e-01
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:4.55%
controls:2.01%
cases:3.25%
controls:0.52%
—
—
—
—
—
—
cases:4.03%
controls:0.40%
cases:8.20%
controls:1.73%
7
31
147
1509
5
8
149
1532
—
—
—
6
6
143
1484
10
21
112
1196
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
8.4e-01
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:4.55%
controls:2.01%
cases:3.25%
controls:0.52%
—
—
—
—
—
—
cases:4.03%
controls:0.40%
cases:8.20%
controls:1.73%
7
31
147
1509
5
8
149
1532
—
—
—
6
6
143
1484
10
21
112
1196
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
8.4e-01
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:4.55%
controls:2.01%
cases:3.25%
controls:0.52%
—
—
—
—
—
—
cases:4.03%
controls:0.40%
cases:8.20%
controls:1.73%
7
31
147
1509
5
8
149
1532
—
—
—
6
6
143
1484
10
21
112
1196
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
2.8e-01
6.5e-01
1.4e+00
—
1.0e+00
7.2e-01
4.1e-01
cases:35.71%
controls:29.68%
cases:30.52%
controls:18.70%
cases:14.29%
controls:3.77%
—
—
cases:11.04%
controls:4.16%
cases:33.56%
controls:19.80%
cases:46.72%
controls:36.89%
55
457
99
1083
47
288
107
1252
22
58
132
1482
—
17
64
137
1473
50
295
99
1195
57
449
65
768
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
4.4e-01
6.5e-01
1.2e+00
—
1.1e+00
6.9e-01
3.3e-01
cases:33.77%
controls:24.68%
cases:34.42%
controls:21.56%
cases:14.29%
controls:5.00%
—
—
cases:13.64%
controls:5.20%
cases:34.90%
controls:21.14%
cases:44.26%
controls:36.24%
52
380
102
1160
53
332
101
1208
22
77
132
1463
—
21
80
133
1457
52
315
97
1175
54
441
68
776
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
1.1e+00
8.4e-01
—
—
—
1.8e+00
2.3e-01
cases:12.34%
controls:4.29%
cases:3.25%
controls:1.43%
—
—
—
—
—
—
cases:5.37%
controls:0.94%
cases:4.92%
controls:3.94%
19
66
135
1474
5
22
149
1518
—
—
—
8
14
141
1476
6
48
116
1169
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
1.2e+00
2.7e+00
—
—
—
—
—
cases:4.55%
controls:1.43%
cases:4.55%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
7
22
147
1518
7
5
147
1535
—
—
—
—
—
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
8.7e-01
1.0e+00
—
—
—
2.6e+00
1.2e+00
cases:5.84%
controls:2.53%
cases:3.90%
controls:1.43%
—
—
—
—
—
—
cases:10.74%
controls:0.87%
cases:9.02%
controls:2.88%
9
39
145
1501
6
22
148
1518
—
—
—
16
13
133
1477
11
35
111
1182
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
2030-5 [3028653]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.34%
—
—
—
—
—
—
—
6
5
143
1485
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
2615-3 [3006217]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.34%
—
—
—
—
—
—
—
6
5
143
1485
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.40%
—
—
—
—
—
—
—
7
6
142
1484
—
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
59275-8 [40762366]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.40%
—
—
—
—
—
—
—
7
6
142
1484
—
Pulmonary Disease
29 [38004472]
29 [38004472]
5.6e-01
1.2e+00
8.9e-01
—
—
1.1e+00
7.3e-01
cases:16.88%
controls:10.39%
cases:16.23%
controls:5.78%
cases:3.25%
controls:1.36%
—
—
—
—
cases:14.09%
controls:5.10%
cases:19.67%
controls:10.60%
26
160
128
1380
25
89
129
1451
5
21
149
1519
—
—
21
76
128
1414
24
129
98
1088
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
—
1.9e+00
—
—
—
2.2e+00
—
—
—
cases:3.25%
controls:0.52%
—
—
—
—
—
—
cases:4.70%
controls:0.54%
—
—
—
5
8
149
1532
—
—
—
7
8
142
1482
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
7.1e-01
—
—
—
—
2.1e+00
—
cases:3.25%
controls:1.62%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.67%
—
—
5
25
149
1515
—
—
—
—
8
10
141
1480
—
cyanocobalamin; nasal, oral, parenteral
B03BA01 [21601121]
B03BA01 [21601121]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.92%
controls:0.66%
—
—
—
—
—
—
6
8
116
1209
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
I87.2 [45552867]
—
—
—
—
—
2.0e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.54%
cases:4.10%
controls:0.99%
—
—
—
—
—
6
8
143
1482
5
12
117
1205
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
3.0e-01
4.9e-01
1.2e+00
—
8.8e-01
5.1e-01
8.7e-02
cases:43.51%
controls:36.36%
cases:42.21%
controls:30.97%
cases:20.13%
controls:7.34%
—
—
cases:14.94%
controls:6.77%
cases:42.95%
controls:31.14%
cases:51.64%
controls:49.47%
67
560
87
980
65
477
89
1063
31
113
123
1427
—
23
104
131
1433
64
464
85
1026
63
602
59
615
Gastroenterology
10 [38004455]
10 [38004455]
4.9e-01
9.5e-01
—
1.0e+50
1.0e+50
2.0e+00
7.9e-01
cases:8.44%
controls:5.32%
cases:5.84%
controls:2.34%
—
—
cases:24.03%
controls:0.00%
cases:5.19%
controls:0.00%
cases:12.75%
controls:1.88%
cases:13.11%
controls:6.41%
13
82
141
1458
9
36
145
1504
—
37
0
117
1540
8
0
146
1537
19
28
130
1462
16
78
106
1139
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
3.1e-01
—
—
—
—
2.0e+00
—
cases:3.25%
controls:2.40%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.74%
—
—
5
37
149
1503
—
—
—
—
8
11
141
1479
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
5.6e-01
—
—
—
—
2.0e+00
—
cases:3.25%
controls:1.88%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.74%
—
—
5
29
149
1511
—
—
—
—
8
11
141
1479
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
4.7e-01
9.8e-01
—
—
—
1.0e+00
5.0e-02
cases:17.53%
controls:11.69%
cases:14.29%
controls:5.91%
—
—
—
—
—
—
cases:13.42%
controls:5.37%
cases:14.75%
controls:14.13%
27
180
127
1360
22
91
132
1449
—
—
—
20
80
129
1410
18
172
104
1045
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
7.2e-01
1.7e+00
—
—
—
2.0e+00
4.6e-01
cases:4.55%
controls:2.27%
cases:3.90%
controls:0.71%
—
—
—
—
—
—
cases:6.71%
controls:1.01%
cases:5.74%
controls:3.70%
7
35
147
1505
6
11
148
1529
—
—
—
10
15
139
1475
7
45
115
1172
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
4.6e-01
1.2e+00
—
—
—
1.9e+00
8.6e-01
cases:7.79%
controls:5.06%
cases:5.84%
controls:1.88%
—
—
—
—
—
—
cases:8.72%
controls:1.34%
cases:9.02%
controls:4.03%
12
78
142
1462
9
29
145
1511
—
—
—
13
20
136
1470
11
49
111
1168
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
3.1e-01
—
—
—
—
1.9e+00
—
cases:3.25%
controls:2.40%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.81%
—
—
5
37
149
1503
—
—
—
—
8
12
141
1478
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
3.1e-01
—
—
—
—
1.9e+00
—
cases:3.25%
controls:2.40%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.81%
—
—
5
37
149
1503
—
—
—
—
8
12
141
1478
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
3.1e-01
—
—
—
—
1.9e+00
—
cases:3.25%
controls:2.40%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.81%
—
—
5
37
149
1503
—
—
—
—
8
12
141
1478
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
3.1e-01
—
—
—
—
1.9e+00
—
cases:3.25%
controls:2.40%
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.81%
—
—
5
37
149
1503
—
—
—
—
8
12
141
1478
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
2.5e-01
4.1e-01
9.9e-01
—
9.4e-01
4.6e-01
1.1e-01
cases:35.06%
controls:29.68%
cases:32.47%
controls:24.16%
cases:14.29%
controls:5.84%
—
—
cases:12.34%
controls:5.20%
cases:32.21%
controls:23.02%
cases:40.98%
controls:38.46%
54
457
100
1083
50
372
104
1168
22
90
132
1450
—
19
80
135
1457
48
343
101
1147
50
468
72
749
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
3.5e-01
6.0e-01
1.2e+00
—
8.7e-01
6.8e-01
2.9e-01
cases:33.77%
controls:26.43%
cases:33.77%
controls:21.82%
cases:15.58%
controls:5.06%
—
—
cases:11.04%
controls:4.94%
cases:38.26%
controls:23.89%
cases:45.90%
controls:38.87%
52
407
102
1133
52
336
102
1204
24
78
130
1462
—
17
76
137
1461
57
356
92
1134
56
473
66
744
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
5.3e-01
1.2e+00
—
—
—
1.9e+00
8.5e-01
cases:11.04%
controls:6.82%
cases:7.14%
controls:2.34%
—
—
—
—
—
—
cases:10.74%
controls:1.74%
cases:11.48%
controls:5.26%
17
105
137
1435
11
36
143
1504
—
—
—
16
26
133
1464
14
64
108
1153
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
1.0e-01
9.6e-01
—
—
—
9.5e-01
3.9e-01
cases:12.34%
controls:11.30%
cases:12.99%
controls:5.39%
—
—
—
—
—
—
cases:12.75%
controls:5.37%
cases:18.85%
controls:13.56%
19
174
135
1366
20
83
134
1457
—
—
—
19
80
130
1410
23
165
99
1052
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
2.1e-01
3.7e-01
1.0e+00
—
8.0e-01
4.5e-01
3.1e-02
cases:44.16%
controls:38.96%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.62%
cases:52.46%
controls:51.68%
68
600
86
940
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
501
83
989
64
629
58
588
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
1.9e-01
3.7e-01
1.0e+00
—
8.0e-01
4.6e-01
3.4e-02
cases:43.51%
controls:38.90%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.42%
cases:52.46%
controls:51.60%
67
599
87
941
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
498
83
992
64
628
58
589
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
1.9e-01
3.7e-01
1.0e+00
—
8.0e-01
4.6e-01
3.4e-02
cases:43.51%
controls:38.90%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.42%
cases:52.46%
controls:51.60%
67
599
87
941
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
498
83
992
64
628
58
589
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
1.9e-01
3.7e-01
1.0e+00
—
8.0e-01
4.8e-01
3.8e-02
cases:43.51%
controls:38.83%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.09%
cases:52.46%
controls:51.52%
67
598
87
942
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
493
83
997
64
627
58
590
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
1.9e-01
3.7e-01
1.0e+00
—
8.0e-01
4.7e-01
3.8e-02
cases:43.51%
controls:38.96%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.22%
cases:52.46%
controls:51.52%
67
600
87
940
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
495
83
995
64
627
58
590
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
2.0e-01
3.7e-01
1.0e+00
—
8.0e-01
4.6e-01
3.8e-02
cases:43.51%
controls:38.77%
cases:42.21%
controls:33.44%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.00%
cases:44.30%
controls:33.42%
cases:52.46%
controls:51.52%
67
597
87
943
65
515
89
1025
31
127
123
1413
—
25
123
129
1414
66
498
83
992
64
627
58
590
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
6.9e-01
—
—
—
—
1.8e+00
1.0e+00
cases:4.55%
controls:2.34%
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.81%
cases:6.56%
controls:2.47%
7
36
147
1504
—
—
—
—
7
12
142
1478
8
30
114
1187
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
3.3e-01
1.8e+00
—
—
—
—
5.3e-01
cases:8.44%
controls:6.23%
cases:4.55%
controls:0.78%
—
—
—
—
—
—
—
—
cases:5.74%
controls:3.45%
13
96
141
1444
7
12
147
1528
—
—
—
—
7
42
115
1175
Internal Medicine
11 [38004456]
11 [38004456]
4.2e-01
8.8e-01
8.6e-01
—
7.9e-01
9.1e-01
3.5e-01
cases:31.82%
controls:23.51%
cases:21.43%
controls:10.19%
cases:3.90%
controls:1.69%
—
—
cases:3.25%
controls:1.50%
cases:20.81%
controls:9.60%
cases:31.15%
controls:24.24%
49
362
105
1178
33
157
121
1383
6
26
148
1514
—
5
23
149
1514
31
143
118
1347
38
295
84
922
Inpatient Visit
IP [9201]
IP [9201]
3.4e-01
7.5e-01
—
—
—
1.8e+00
6.1e-01
cases:11.69%
controls:8.64%
cases:6.49%
controls:3.18%
—
—
—
—
—
—
cases:12.08%
controls:2.28%
cases:10.66%
controls:6.08%
18
133
136
1407
10
49
144
1491
—
—
—
18
34
131
1456
13
74
109
1143
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
4.9e-01
9.7e-01
1.0e+00
—
5.0e-01
7.9e-01
4.4e-01
cases:28.57%
controls:19.61%
cases:25.32%
controls:11.36%
cases:5.84%
controls:2.14%
—
—
cases:3.90%
controls:2.41%
cases:23.49%
controls:12.21%
cases:32.79%
controls:23.83%
44
302
110
1238
39
175
115
1365
9
33
145
1507
—
6
37
148
1500
35
182
114
1308
40
290
82
927
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
9.8e-01
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:4.55%
controls:1.75%
cases:3.25%
controls:0.39%
—
—
—
—
—
—
cases:3.36%
controls:0.34%
cases:8.20%
controls:1.56%
7
27
147
1513
5
6
149
1534
—
—
—
5
5
144
1485
10
19
112
1198
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
9.8e-01
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:4.55%
controls:1.75%
cases:3.25%
controls:0.39%
—
—
—
—
—
—
cases:3.36%
controls:0.34%
cases:8.20%
controls:1.56%
7
27
147
1513
5
6
149
1534
—
—
—
5
5
144
1485
10
19
112
1198
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
9.8e-01
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:4.55%
controls:1.75%
cases:3.25%
controls:0.39%
—
—
—
—
—
—
cases:3.36%
controls:0.34%
cases:8.20%
controls:1.56%
7
27
147
1513
5
6
149
1534
—
—
—
5
5
144
1485
10
19
112
1198
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
9.8e-01
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:4.55%
controls:1.75%
cases:3.25%
controls:0.39%
—
—
—
—
—
—
cases:3.36%
controls:0.34%
cases:8.20%
controls:1.56%
7
27
147
1513
5
6
149
1534
—
—
—
5
5
144
1485
10
19
112
1198
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
9.8e-01
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:4.55%
controls:1.75%
cases:3.25%
controls:0.39%
—
—
—
—
—
—
cases:3.36%
controls:0.34%
cases:8.20%
controls:1.56%
7
27
147
1513
5
6
149
1534
—
—
—
5
5
144
1485
10
19
112
1198
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
K21.9 [45538509]
1.7e+00
—
—
1.0e+50
—
—
1.7e+00
cases:3.25%
controls:0.58%
—
—
—
—
cases:5.19%
controls:0.00%
—
—
—
—
cases:6.56%
controls:1.23%
5
9
149
1531
—
—
8
0
146
1540
—
—
8
15
114
1202
Emergency Room Visit
ER [9203]
ER [9203]
3.9e-01
7.5e-01
8.2e-01
—
—
9.4e-01
2.2e-01
cases:40.91%
controls:31.88%
cases:20.78%
controls:11.04%
cases:3.90%
controls:1.75%
—
—
—
—
cases:23.49%
controls:10.74%
cases:34.43%
controls:29.66%
63
491
91
1049
32
170
122
1370
6
27
148
1513
—
—
35
160
114
1330
42
361
80
856
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
8.3e-01
1.3e+00
—
—
—
1.7e+00
1.1e+00
cases:7.14%
controls:3.25%
cases:6.49%
controls:1.88%
—
—
—
—
—
—
cases:6.71%
controls:1.34%
cases:10.66%
controls:3.86%
11
50
143
1490
10
29
144
1511
—
—
—
10
20
139
1470
13
47
109
1170
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
5.6e-01
3.0e-01
1.6e+00
—
1.1e+00
7.0e-01
2.1e-02
cases:29.87%
controls:19.55%
cases:14.29%
controls:11.04%
cases:6.49%
controls:1.43%
—
—
cases:5.84%
controls:1.95%
cases:20.13%
controls:11.14%
cases:27.87%
controls:27.44%
46
301
108
1239
22
170
132
1370
10
22
144
1518
—
9
30
145
1507
30
166
119
1324
34
334
88
883
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
6.4e-01
-2.0e-02
—
1.0e+50
—
1.5e+00
5.4e-01
cases:16.23%
controls:9.29%
cases:3.25%
controls:3.31%
—
—
cases:3.25%
controls:0.00%
—
—
cases:9.40%
controls:2.21%
cases:12.30%
controls:7.56%
25
143
129
1397
5
51
149
1489
—
5
0
149
1540
—
14
33
135
1457
15
92
107
1125
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
3.2e-01
6.8e-01
2.0e+00
—
—
1.5e+00
7.1e-01
cases:14.29%
controls:10.78%
cases:7.79%
controls:4.09%
cases:3.25%
controls:0.45%
—
—
—
—
cases:11.41%
controls:2.82%
cases:16.39%
controls:8.79%
22
166
132
1374
12
63
142
1477
5
7
149
1533
—
—
17
42
132
1448
20
107
102
1110
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
4.9e-01
1.4e+00
—
—
—
9.4e-01
6.0e-01
cases:9.09%
controls:5.78%
cases:8.44%
controls:2.21%
—
—
—
—
—
—
cases:4.70%
controls:1.88%
cases:12.30%
controls:7.15%
14
89
140
1451
13
34
141
1506
—
—
—
7
28
142
1462
15
87
107
1130
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
5.1e-01
1.4e+00
—
—
—
—
2.8e-01
cases:10.39%
controls:6.49%
cases:7.79%
controls:2.08%
—
—
—
—
—
—
—
—
cases:9.02%
controls:6.98%
16
100
138
1440
12
32
142
1508
—
—
—
—
11
85
111
1132
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
7.4e-01
1.4e+00
—
—
-1.0e+50
8.4e-01
8.6e-01
cases:9.09%
controls:4.55%
cases:8.44%
controls:2.27%
—
—
—
—
cases:0.00%
controls:0.46%
cases:4.70%
controls:2.08%
cases:9.02%
controls:4.03%
14
70
140
1470
13
35
141
1505
—
—
0
7
154
1530
7
31
142
1459
11
49
111
1168
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.5e-01
8.3e-01
—
—
—
1.3e+00
2.4e-01
cases:10.39%
controls:9.09%
cases:5.19%
controls:2.34%
—
—
—
—
—
—
cases:8.72%
controls:2.48%
cases:9.02%
controls:7.23%
16
140
138
1400
8
36
146
1504
—
—
—
13
37
136
1453
11
88
111
1129
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
3.6e-01
1.3e+00
—
—
-1.0e+50
7.0e-01
-2.7e-01
cases:7.79%
controls:5.58%
cases:7.79%
controls:2.21%
—
—
—
—
cases:0.00%
controls:0.59%
cases:5.37%
controls:2.75%
cases:5.74%
controls:7.40%
12
86
142
1454
12
34
142
1506
—
—
0
9
154
1528
8
41
141
1449
7
90
115
1127
General Surgery
2 [38004447]
2 [38004447]
5.3e-01
7.7e-01
—
1.0e+50
—
1.3e+00
-1.5e-01
cases:26.62%
controls:17.66%
cases:11.69%
controls:5.78%
—
—
cases:9.09%
controls:0.00%
—
—
cases:19.46%
controls:6.11%
cases:13.11%
controls:14.95%
41
272
113
1268
18
89
136
1451
—
14
0
140
1540
—
29
91
120
1399
16
182
106
1035
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
6.5e-01
7.8e-01
1.3e+00
—
1.4e+00
1.3e+00
7.8e-01
cases:17.53%
controls:10.00%
cases:11.04%
controls:5.39%
cases:4.55%
controls:1.23%
—
—
cases:3.25%
controls:0.85%
cases:15.44%
controls:4.77%
cases:21.31%
controls:11.09%
27
154
127
1386
17
83
137
1457
7
19
147
1521
—
5
13
149
1524
23
71
126
1419
26
135
96
1082
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
4.3e-01
1.3e+00
—
—
—
7.5e-01
5.7e-01
cases:9.09%
controls:6.10%
cases:9.74%
controls:2.92%
—
—
—
—
—
—
cases:6.71%
controls:3.29%
cases:16.39%
controls:9.94%
14
94
140
1446
15
45
139
1495
—
—
—
10
49
139
1441
20
121
102
1096
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
2.6e-01
—
—
—
-1.0e+50
4.7e-01
1.3e+00
cases:5.84%
controls:4.55%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:4.03%
controls:2.55%
cases:12.30%
controls:3.78%
9
70
145
1470
—
—
—
0
5
154
1532
6
38
143
1452
15
46
107
1171
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
1.3e+00
—
—
—
—
—
2.0e+00
cases:7.79%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.58%
12
36
142
1504
—
—
—
—
—
5
7
117
1210
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
6.1e-01
6.6e-01
3.3e-01
1.2e+00
3.7e-01
6.7e-01
7.6e-01
cases:97.40%
controls:95.32%
cases:92.86%
controls:87.08%
cases:57.14%
controls:48.96%
cases:8.44%
controls:2.66%
cases:60.39%
controls:51.27%
cases:92.62%
controls:86.51%
cases:97.54%
controls:94.91%
150
1468
4
72
143
1341
11
199
88
754
66
786
13
41
141
1499
93
788
61
749
138
1289
11
201
119
1155
3
62
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
4.5e-01
7.0e-01
1.6e+00
—
1.4e+00
1.2e+00
5.9e-01
cases:19.48%
controls:13.38%
cases:11.69%
controls:6.17%
cases:3.90%
controls:0.78%
—
—
cases:3.25%
controls:0.85%
cases:17.45%
controls:6.17%
cases:25.41%
controls:15.86%
30
206
124
1334
18
95
136
1445
6
12
148
1528
—
5
13
149
1524
26
92
123
1398
31
193
91
1024
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
7.1e-01
5.2e-01
—
—
—
1.1e+00
2.4e-01
cases:14.29%
controls:7.60%
cases:5.84%
controls:3.57%
—
—
—
—
—
—
cases:8.72%
controls:2.95%
cases:10.66%
controls:8.55%
22
117
132
1423
9
55
145
1485
—
—
—
13
44
136
1446
13
104
109
1113
Outpatient Hospital
22 [8756]
22 [8756]
5.4e-01
3.9e-01
1.4e+00
—
1.8e+00
1.1e+00
5.5e-01
cases:35.71%
controls:24.42%
cases:10.39%
controls:7.27%
cases:4.55%
controls:1.10%
—
—
cases:3.90%
controls:0.65%
cases:17.45%
controls:6.44%
cases:27.05%
controls:17.58%
55
376
99
1164
16
112
138
1428
7
17
147
1523
—
6
10
148
1527
26
96
123
1394
33
214
89
1003
Inpatient Hospital
21 [8717]
21 [8717]
4.5e-01
2.7e-01
6.9e-01
—
9.5e-01
1.1e+00
2.3e-01
cases:44.16%
controls:33.57%
cases:16.23%
controls:12.86%
cases:4.55%
controls:2.34%
—
—
cases:5.19%
controls:2.08%
cases:27.52%
controls:11.54%
cases:31.15%
controls:26.38%
68
517
86
1023
25
198
129
1342
7
36
147
1504
—
8
32
146
1505
41
172
108
1318
38
321
84
896
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
1.9e-01
3.8e-01
1.0e+00
—
7.9e-01
4.6e-01
3.1e-02
cases:43.51%
controls:38.96%
cases:42.21%
controls:33.38%
cases:20.13%
controls:8.25%
—
—
cases:16.23%
controls:8.07%
cases:44.30%
controls:33.36%
cases:52.46%
controls:51.68%
67
600
87
940
65
514
89
1026
31
127
123
1413
—
25
124
129
1413
66
497
83
993
64
629
58
588
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.2e-01
8.0e-01
—
—
—
1.0e+00
5.4e-01
cases:12.34%
controls:10.13%
cases:11.04%
controls:5.26%
—
—
—
—
—
—
cases:11.41%
controls:4.43%
cases:16.39%
controls:10.27%
19
156
135
1384
17
81
137
1459
—
—
—
17
66
132
1424
20
125
102
1092
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.0e+00
1.0e+00
-1.0e+50
—
—
9.1e-01
6.9e-01
cases:10.39%
controls:4.03%
cases:5.84%
controls:2.21%
cases:0.00%
controls:0.45%
—
—
—
—
cases:4.70%
controls:1.95%
cases:10.66%
controls:5.67%
16
62
138
1478
9
34
145
1506
0
7
154
1533
—
—
7
29
142
1461
13
69
109
1148
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
5.0e-01
1.0e+00
9.8e-01
—
—
6.9e-01
2.9e-01
cases:18.18%
controls:11.88%
cases:16.88%
controls:6.95%
cases:3.90%
controls:1.49%
—
—
—
—
cases:12.75%
controls:6.85%
cases:18.03%
controls:14.13%
28
183
126
1357
26
107
128
1433
6
23
148
1517
—
—
19
102
130
1388
22
172
100
1045
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
1.7e-01
3.1e-01
9.9e-01
—
7.7e-01
3.2e-01
-9.7e-02
cases:37.66%
controls:33.77%
cases:27.27%
controls:21.62%
cases:11.69%
controls:4.68%
—
—
cases:8.44%
controls:4.10%
cases:25.50%
controls:19.87%
cases:38.52%
controls:40.84%
58
520
96
1020
42
333
112
1207
18
72
136
1468
—
13
63
141
1474
38
296
111
1194
47
497
75
720
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.9e-01
5.5e-01
9.8e-01
—
8.4e-01
5.2e-01
2.0e-01
cases:39.61%
controls:35.13%
cases:39.61%
controls:27.40%
cases:14.94%
controls:6.17%
—
—
cases:12.34%
controls:5.73%
cases:39.60%
controls:28.12%
cases:50.82%
controls:45.93%
61
541
93
999
61
422
93
1118
23
95
131
1445
—
19
88
135
1449
59
419
90
1071
62
559
60
658
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
2.4e-01
5.2e-01
9.6e-01
—
8.5e-01
5.2e-01
2.1e-01
cases:40.26%
controls:34.74%
cases:38.31%
controls:27.01%
cases:14.29%
controls:5.97%
—
—
cases:12.34%
controls:5.66%
cases:39.60%
controls:28.05%
cases:50.82%
controls:45.60%
62
535
92
1005
59
416
95
1124
22
92
132
1448
—
19
87
135
1450
59
418
90
1072
62
555
60
662
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.0e-01
9.5e-01
—
—
—
3.9e-01
4.9e-01
cases:13.64%
controls:8.70%
cases:11.69%
controls:4.87%
—
—
—
—
—
—
cases:6.71%
controls:4.63%
cases:13.11%
controls:8.46%
21
134
133
1406
18
75
136
1465
—
—
—
10
69
139
1421
16
103
106
1114
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
5.4e-02
2.4e-01
—
—
-1.0e+50
4.1e-01
9.1e-01
cases:14.29%
controls:13.64%
cases:5.84%
controls:4.68%
—
—
—
—
cases:0.00%
controls:0.39%
cases:6.71%
controls:4.56%
cases:19.67%
controls:8.96%
22
210
132
1330
9
72
145
1468
—
—
0
6
154
1531
10
68
139
1422
24
109
98
1108
salbutamol; inhalant
R03AC02 [21603256]
R03AC02 [21603256]
6.0e-01
8.9e-01
—
—
9.3e-01
8.0e-01
3.8e-01
cases:19.48%
controls:11.75%
cases:14.94%
controls:6.75%
—
—
—
—
cases:3.25%
controls:1.30%
cases:13.42%
controls:6.51%
cases:22.13%
controls:16.27%
30
181
124
1359
23
104
131
1436
—
—
5
20
149
1517
20
97
129
1393
27
198
95
1019
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
3.9e-01
8.6e-01
9.8e-01
—
—
6.4e-01
2.3e-01
cases:16.23%
controls:11.62%
cases:14.29%
controls:6.56%
cases:3.90%
controls:1.49%
—
—
—
—
cases:12.08%
controls:6.78%
cases:16.39%
controls:13.48%
25
179
129
1361
22
101
132
1439
6
23
148
1517
—
—
18
101
131
1389
20
164
102
1053
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
4.0e-01
8.6e-01
9.8e-01
—
—
6.4e-01
2.3e-01
cases:16.23%
controls:11.49%
cases:14.29%
controls:6.56%
cases:3.90%
controls:1.49%
—
—
—
—
cases:12.08%
controls:6.78%
cases:16.39%
controls:13.48%
25
177
129
1363
22
101
132
1439
6
23
148
1517
—
—
18
101
131
1389
20
164
102
1053
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
3.6e-01
8.4e-01
8.4e-01
—
—
6.7e-01
1.5e-01
cases:18.83%
controls:13.90%
cases:17.53%
controls:8.38%
cases:4.55%
controls:2.01%
—
—
—
—
cases:14.77%
controls:8.12%
cases:18.03%
controls:15.94%
29
214
125
1326
27
129
127
1411
7
31
147
1509
—
—
22
121
127
1369
22
194
100
1023
Emergency Medicine
93 [38004510]
93 [38004510]
3.5e-01
8.4e-01
—
1.0e+50
—
6.4e-01
4.1e-01
cases:18.18%
controls:13.57%
cases:15.58%
controls:7.40%
—
—
cases:4.55%
controls:0.00%
—
—
cases:13.42%
controls:7.58%
cases:27.05%
controls:19.80%
28
209
126
1331
24
114
130
1426
—
7
0
147
1540
—
20
113
129
1377
33
241
89
976
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
4.3e-01
8.4e-01
1.3e+00
—
—
6.1e-01
3.2e-01
cases:25.32%
controls:18.12%
cases:17.53%
controls:8.44%
cases:5.19%
controls:1.49%
—
—
—
—
cases:16.11%
controls:9.46%
cases:27.05%
controls:21.20%
39
279
115
1261
27
130
127
1410
8
23
146
1517
—
—
24
141
125
1349
33
258
89
959
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
8090/3-C44.3 [44499724]
8090/3-C44.3 [44499724]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
piroxicam; ointment
M02AA07 [21604043]
M02AA07 [21604043]
5.2e-01
—
—
—
-1.0e+50
-1.0e+50
—
cases:5.84%
controls:3.57%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.94%
—
—
9
55
145
1485
—
—
—
0
5
154
1532
0
14
149
1476
—
Prostate specific Ag panel - Serum or Plasma
53764-7 [3039443]
53764-7 [3039443]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
122
1210
aripiprazole; oral, parenteral
N05AX12 [21604562]
N05AX12 [21604562]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.32%
—
—
—
—
cases:0.00%
controls:0.81%
cases:0.00%
controls:0.99%
0
11
154
1529
0
10
154
1530
0
5
154
1535
—
—
0
12
149
1478
0
12
122
1205
Rosacea, unspecified
L71.9 [45548204]
L71.9 [45548204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Risk factor cardiovascular disease
K22 [2002000551]
K22 [2002000551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Parkinson disease
G20 [45538098]
G20 [45538098]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
0
7
154
1533
0
6
154
1534
—
—
—
0
7
149
1483
—
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
-1.4e-01
2.1e-01
—
—
—
1.4e-01
3.0e-02
cases:8.44%
controls:9.55%
cases:9.09%
controls:7.47%
—
—
—
—
—
—
cases:9.40%
controls:8.26%
cases:11.48%
controls:11.18%
13
147
141
1393
14
115
140
1425
—
—
—
14
123
135
1367
14
136
108
1081
hydroxyzine; oral, parenteral
N05BB01 [21604590]
N05BB01 [21604590]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
0
13
154
1527
—
—
—
—
—
Boil/carbuncle
S10 [2002000975]
S10 [2002000975]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
—
1.3e+00
—
—
—
—
—
—
—
cases:3.25%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
5
14
149
1526
—
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
14927-8 [3025839]
4.2e-02
6.8e-01
—
—
—
1.9e-01
1.9e-01
cases:3.25%
controls:3.12%
cases:5.84%
controls:3.05%
—
—
—
—
—
—
cases:5.37%
controls:4.50%
cases:14.75%
controls:12.57%
5
48
149
1492
9
47
145
1493
—
—
—
8
67
141
1423
18
153
104
1064
varenicline; oral
N07BA03 [21604819]
N07BA03 [21604819]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
9
154
1531
—
—
—
—
—
0
6
122
1211
Skin, Other therap proced/minor surg NEC
S59 [2002001023]
S59 [2002001023]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
tranexamic acid; oral, parenteral
B02AA02 [21601036]
B02AA02 [21601036]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
13
154
1527
—
—
—
—
—
0
8
122
1209
Speech audiometry
252592009 [4091138]
252592009 [4091138]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
10
122
1207
Biopsy of prostate with ultrasoudnguidance
KE1AT [2001306172]
KE1AT [2001306172]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:0.74%
—
—
—
—
—
—
5
9
117
1208
Ankylosing spondylitis
M45 [45591841]
M45 [45591841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Gonarthrosis, unspecified
M17.9 [45606128]
M17.9 [45606128]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
0
11
149
1479
—
apixaban; oral
B01AF02 [43534762]
B01AF02 [43534762]
1.0e+00
8.6e-01
—
—
1.5e+00
8.0e-01
3.1e-01
cases:5.19%
controls:1.88%
cases:5.19%
controls:2.27%
—
—
—
—
cases:3.90%
controls:0.91%
cases:6.04%
controls:2.82%
cases:5.74%
controls:4.27%
8
29
146
1511
8
35
146
1505
—
—
6
14
148
1523
9
42
140
1448
7
52
115
1165
Atopic dermatitis, unspecified
L20.9 [45548191]
L20.9 [45548191]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.47%
—
—
—
—
—
—
—
5
7
144
1483
—
folic acid
V04CX02 [715877]
V04CX02 [715877]
1.3e+00
1.7e+00
—
—
—
9.4e-01
8.4e-01
cases:3.25%
controls:0.91%
cases:4.55%
controls:0.84%
—
—
—
—
—
—
cases:3.36%
controls:1.34%
cases:4.10%
controls:1.81%
5
14
149
1526
7
13
147
1527
—
—
—
5
20
144
1470
5
22
117
1195
liraglutide; parenteral
A10BJ02 [1123630]
A10BJ02 [1123630]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
206 [2001600204]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
8
154
1532
—
—
—
—
—
antiinfectives, combinations
S02AA30 [21605163]
S02AA30 [21605163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
A10BJ06 [1501778]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
11
154
1529
0
10
154
1530
—
—
—
—
—
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
S83.5 [45608523]
S83.5 [45608523]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
calcium carbonate; oral
A12AA04 [21600863]
A12AA04 [21600863]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
0
6
154
1534
—
—
—
—
0
5
122
1212
Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
66885-5 [40769539]
66885-5 [40769539]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
9
154
1531
—
—
—
—
—
0
6
122
1211
Besnier prurigo
L20.0 [45562534]
L20.0 [45562534]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
9
122
1208
ramipril; oral
C09AA05 [21601789]
C09AA05 [21601789]
1.8e-01
3.8e-01
—
—
6.1e-01
2.1e-01
1.0e-01
cases:8.44%
controls:7.14%
cases:9.09%
controls:6.43%
—
—
—
—
cases:3.90%
controls:2.15%
cases:8.05%
controls:6.64%
cases:9.02%
controls:8.22%
13
110
141
1430
14
99
140
1441
—
—
6
33
148
1504
12
99
137
1391
11
100
111
1117
hydrocortisone and antiinfectives
S02CA03 [21605175]
S02CA03 [21605175]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
14
154
1526
—
—
—
—
—
Extensive examination of musculoskeletal system
SPAT1212 [2001700313]
SPAT1212 [2001700313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
8
122
1209
Photography of fundus of eye
XCK10 [2001301381]
XCK10 [2001301381]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
0
15
149
1475
—
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.8e-01
3.0e-01
—
—
—
5.2e-01
1.8e-01
cases:12.99%
controls:11.10%
cases:5.84%
controls:4.42%
—
—
—
—
—
—
cases:6.71%
controls:4.09%
cases:12.30%
controls:10.52%
20
171
134
1369
9
68
145
1472
—
—
—
10
61
139
1429
15
128
107
1089
Subjective visual disturbances
H53.1 [45557467]
H53.1 [45557467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
0
12
122
1205
Retinal detachment with retinal break
H33.0 [45547857]
H33.0 [45547857]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
7
154
1533
—
—
—
—
—
0
7
122
1210
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
5128-4 [3001334]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
154
1528
—
—
—
—
—
—
hydrocortisone and antiseptics
D07BA04 [21602146]
D07BA04 [21602146]
—
-1.0e+50
—
—
—
—
6.7e-01
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:4.10%
controls:2.14%
—
0
12
154
1528
—
—
—
—
5
26
117
1191
Open wound of other parts of lower leg
S81.8 [45564809]
S81.8 [45564809]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Unspecified urinary incontinence
R32 [45606803]
R32 [45606803]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
acitretin; oral
D05BB02 [21602051]
D05BB02 [21602051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Release of median nerve
ACC51 [2001300642]
ACC51 [2001300642]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
8
122
1209
Migraine with aura [classical migraine]
G43.1 [45562086]
G43.1 [45562086]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
6
154
1534
—
—
—
—
—
0
5
122
1212
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
1961-2 [3015235]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
nimesulide; oral
M01AX17 [21604007]
M01AX17 [21604007]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
—
—
—
0
24
122
1193
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
2857-1 [3013603]
6.8e-02
4.8e-01
—
—
—
-1.9e-01
-1.2e-01
cases:13.64%
controls:12.86%
cases:10.39%
controls:6.69%
—
—
—
—
—
—
cases:7.38%
controls:8.79%
cases:14.75%
controls:16.27%
21
198
133
1342
16
103
138
1437
—
—
—
11
131
138
1359
18
198
104
1019
Stomatognathic treatment, simple
SHA01 [2001310405]
SHA01 [2001310405]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.90%
—
—
—
—
—
0
5
149
1485
0
11
122
1206
Restricted health certificate
SPAT1283 [2001700384]
SPAT1283 [2001700384]
1.1e+00
—
—
—
—
—
—
cases:5.84%
controls:1.95%
—
—
—
—
—
—
—
—
—
—
—
—
9
30
145
1510
—
—
—
—
—
—
Chronic arrhythmias
207 [2001600205]
207 [2001600205]
8.9e-01
—
—
—
—
-1.0e+50
—
cases:5.19%
controls:2.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
8
34
146
1506
—
—
—
—
0
10
149
1480
—
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
12286-1 [3011288]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
122
1210
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-7.7e-02
4.2e-01
8.9e-01
—
—
5.2e-01
2.1e-01
cases:15.58%
controls:16.62%
cases:12.34%
controls:8.44%
cases:3.25%
controls:1.36%
—
—
—
—
cases:12.75%
controls:7.99%
cases:23.77%
controls:20.21%
24
256
130
1284
19
130
135
1410
5
21
149
1519
—
—
19
119
130
1371
29
246
93
971
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:1.15%
—
0
8
154
1532
—
—
—
0
5
149
1485
0
14
122
1203
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
0
8
154
1532
—
—
—
0
14
149
1476
—
Congenital stenosis and stricture of oesophagus
Q39.3 [45592374]
Q39.3 [45592374]
—
—
—
1.0e+50
—
1.0e+50
—
—
—
—
—
—
—
cases:5.84%
controls:0.00%
—
—
cases:4.03%
controls:0.00%
—
—
—
—
—
9
0
145
1540
—
6
0
143
1490
—
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
2.6e-01
1.1e-01
-3.9e-01
—
2.2e-01
1.8e-01
-7.7e-02
cases:24.03%
controls:19.61%
cases:18.83%
controls:17.27%
cases:3.90%
controls:5.65%
—
—
cases:7.14%
controls:5.79%
cases:21.48%
controls:18.59%
cases:20.49%
controls:21.77%
37
302
117
1238
29
266
125
1274
6
87
148
1453
—
11
89
143
1448
32
277
117
1213
25
265
97
952
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
49002-9 [3050449]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.07%
0
10
154
1530
—
—
—
—
0
9
149
1481
0
13
122
1204
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
39480-9 [3038515]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
0
8
154
1532
—
—
—
—
—
0
19
122
1198
Pars plana or pars plicata vitrectomy
CKD65 [2001301417]
CKD65 [2001301417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Preparation of an aid
R5120 [2001310247]
R5120 [2001310247]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
solifenacin; oral
G04BD08 [21602641]
G04BD08 [21602641]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
0
17
154
1523
0
14
154
1526
—
—
—
0
11
149
1479
—
Percutaneous transluminal coronary angioplasty with stent (includes balloon pre-dilation)
FN2BA [2001303090]
FN2BA [2001303090]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
14
122
1203
Foot and toes X-ray examination
NH3AA [2001308267]
NH3AA [2001308267]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
6
154
1534
—
—
—
0
7
149
1483
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
1.1e-01
8.0e-01
—
—
—
5.3e-01
4.0e-01
cases:8.44%
controls:7.60%
cases:8.44%
controls:3.96%
—
—
—
—
—
—
cases:5.37%
controls:3.22%
cases:14.75%
controls:10.35%
13
117
141
1423
13
61
141
1479
—
—
—
8
48
141
1442
18
126
104
1091
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
FN1YT [2001303064]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
budesonide; inhalant
R03BA02 [21603285]
R03BA02 [21603285]
6.1e-01
2.1e-01
—
—
—
3.9e-01
3.9e-01
cases:9.09%
controls:5.13%
cases:3.90%
controls:3.18%
—
—
—
—
—
—
cases:4.70%
controls:3.22%
cases:6.56%
controls:4.52%
14
79
140
1461
6
49
148
1491
—
—
—
7
48
142
1442
8
55
114
1162
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
-3.4e-01
—
—
—
-1.0e+50
—
-3.1e-01
cases:5.84%
controls:7.99%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
cases:4.10%
controls:5.51%
9
123
145
1417
—
—
—
0
5
154
1532
—
5
67
117
1150
Other obesity
E66.8 [45533036]
E66.8 [45533036]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.74%
0
11
154
1529
0
5
154
1535
—
—
—
0
5
149
1485
0
9
122
1208
CPAP therapy
WX723 [2001310826]
WX723 [2001310826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
4533-6 [3024403]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
12841-3 [3001784]
-2.2e-02
3.8e-01
—
—
-1.0e+50
—
-1.6e-01
cases:9.74%
controls:9.94%
cases:6.49%
controls:4.55%
—
—
—
—
cases:0.00%
controls:0.85%
—
—
cases:10.66%
controls:12.33%
15
153
139
1387
10
70
144
1470
—
—
0
13
154
1524
—
13
150
109
1067
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
1.3e-01
—
—
—
—
1.2e+00
2.4e-01
cases:4.55%
controls:4.03%
—
—
—
—
—
—
—
—
cases:4.03%
controls:1.21%
cases:7.38%
controls:5.92%
7
62
147
1478
—
—
—
—
6
18
143
1472
9
72
113
1145
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
NA3AA [2001307026]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
hydrocortisone
S01CB03 [21603666]
S01CB03 [21603666]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
154
1531
—
—
—
—
—
—
Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]
NFB30 [2001307921]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
0
7
154
1533
—
—
—
0
5
149
1485
—
ethinylestradiol; oral
L02AA03 [21603817]
L02AA03 [21603817]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
8.6e-01
9.8e-01
—
—
—
9.4e-01
7.5e-01
cases:7.79%
controls:3.44%
cases:4.55%
controls:1.75%
—
—
—
—
—
—
cases:4.70%
controls:1.88%
cases:6.56%
controls:3.20%
12
53
142
1487
7
27
147
1513
—
—
—
7
28
142
1462
8
39
114
1178
Osteoarthrosis of knee
L90 [2002000709]
L90 [2002000709]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
6
149
1484
—
Emergency care or similar visit
WYA10 [2001310872]
WYA10 [2001310872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Other spondylosis, multiple sites in spine
M47.80 [42617655]
M47.80 [42617655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
—
tetracycline; oral, parenteral
J01AA07 [21602805]
J01AA07 [21602805]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
J01CE10 [21602850]
2.3e-01
—
-1.0e+50
—
—
-2.4e-01
-1.0e-01
cases:14.29%
controls:11.69%
—
—
cases:0.00%
controls:0.52%
—
—
—
—
cases:3.36%
controls:4.23%
cases:9.84%
controls:10.76%
22
180
132
1360
—
0
8
154
1532
—
—
5
63
144
1427
12
131
110
1086
Extraction of multiple teeth
EBA15 [2001301927]
EBA15 [2001301927]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
7
154
1533
—
—
—
—
—
0
5
122
1212
Congenital malformation of oesophagus, unspecified
Q39.9 [45548899]
Q39.9 [45548899]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
149
1540
—
—
—
Aortic (valve) stenosis with insufficiency
I35.2 [45562346]
I35.2 [45562346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
122
1210
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
154
1527
—
—
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
379 [2001600340]
379 [2001600340]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Female infertility, unspecified
N97.9 [45582432]
N97.9 [45582432]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
33959-8 [3046279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
—
Cell count panel - Synovial fluid
34559-5 [3044941]
34559-5 [3044941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
J07AL02 [21601313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
10
122
1207
Disorientation, unspecified
R41.0 [45558469]
R41.0 [45558469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
—
alprostadil; parenteral
C01EA01 [21600362]
C01EA01 [21600362]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Fracture of tooth root
S02.53 [2000503620]
S02.53 [2000503620]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Repair work or maintenance done on the aid
R5130 [2001310248]
R5130 [2001310248]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
0
6
154
1534
—
—
—
—
0
6
149
1484
—
Other benign neoplasms of skin
D23 [45590988]
D23 [45590988]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
122
1210
Deposits [accretions] on teeth betel
K03.65 [2000502690]
K03.65 [2000502690]
-1.2e-01
—
—
—
—
—
5.2e-01
cases:3.25%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:2.47%
5
56
149
1484
—
—
—
—
—
5
30
117
1187
Giving the first information
R2110 [2001310194]
R2110 [2001310194]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
0
6
154
1534
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
M02AA15 [21604051]
5.8e-01
—
—
—
—
—
—
cases:3.90%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
34
148
1506
—
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
G04BE03 [21602648]
-2.2e-01
—
-1.0e+50
—
—
4.1e-01
1.6e-01
cases:3.90%
controls:4.81%
—
—
cases:0.00%
controls:0.45%
—
—
—
—
cases:4.70%
controls:3.15%
cases:5.74%
controls:4.93%
6
74
148
1466
—
0
7
154
1533
—
—
7
47
142
1443
7
60
115
1157
Anxiety disorder/anxiety state
P74 [2002000868]
P74 [2002000868]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Shortness of breath/dyspnoea
R02 [2002000883]
R02 [2002000883]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:4.55%
controls:1.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
7
23
147
1517
—
—
—
—
0
8
149
1482
—
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
5.3e-01
5.9e-01
—
—
—
1.4e+00
-2.6e-03
cases:8.44%
controls:5.13%
cases:3.25%
controls:1.82%
—
—
—
—
—
—
cases:5.37%
controls:1.34%
cases:4.92%
controls:4.93%
13
79
141
1461
5
28
149
1512
—
—
—
8
20
141
1470
6
60
116
1157
Disease/condition unspecnature/site
A99 [2002000232]
A99 [2002000232]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
12
154
1528
—
—
—
—
—
Balloon angioplasty and drug eluding stent
AN4 [2000200166]
AN4 [2000200166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
-3.6e-01
-2.3e-01
-1.0e+50
—
—
-5.7e-01
-1.5e-01
cases:6.49%
controls:9.09%
cases:5.19%
controls:6.43%
cases:0.00%
controls:0.91%
—
—
—
—
cases:4.03%
controls:6.91%
cases:12.30%
controls:13.97%
10
140
144
1400
8
99
146
1441
0
14
154
1526
—
—
6
103
143
1387
15
170
107
1047
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
8.1e-01
-1.0e+50
—
—
—
—
—
cases:4.55%
controls:2.08%
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
7
32
147
1508
0
17
154
1523
—
—
—
—
—
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
23826-1 [3012477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
10
122
1207
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
3.2e-02
—
-1.0e+50
—
-1.0e+50
—
-1.9e-01
cases:9.09%
controls:8.83%
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.46%
—
—
cases:6.56%
controls:7.81%
14
136
140
1404
—
0
10
154
1530
—
0
7
154
1530
—
8
95
114
1122
disulfiram; oral
N07BB01 [21604821]
N07BB01 [21604821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
154
1531
—
—
—
—
—
—
valsartan; oral
C09CA03 [21601826]
C09CA03 [21601826]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
8
154
1532
—
—
—
—
sulfasalazine; oral, rectal
A07EC01 [21600663]
A07EC01 [21600663]
1.2e+00
—
—
—
—
—
—
cases:3.25%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
149
1524
—
—
—
—
—
—
Other intraoperative electrophysiological investigation in arhythmia or disturbance of impulse propagation
XFP96 [2001303143]
XFP96 [2001303143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
—
5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma
50149-4 [3030136]
50149-4 [3030136]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
6.4e-01
—
—
—
—
—
8.0e-01
cases:7.14%
controls:3.90%
—
—
—
—
—
—
—
—
—
—
cases:6.56%
controls:3.04%
11
60
143
1480
—
—
—
—
—
8
37
114
1180
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
CKD05 [2001301407]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.90%
0
8
154
1532
0
6
154
1534
—
—
—
0
9
149
1481
0
11
122
1206
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
-1.5e-02
—
—
—
—
—
3.6e-01
cases:4.55%
controls:4.61%
—
—
—
—
—
—
—
—
—
—
cases:9.02%
controls:6.49%
7
71
147
1469
—
—
—
—
—
11
79
111
1138
Ocular pain
H57.1 [45596140]
H57.1 [45596140]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Unspecified dementia
F03 [45566772]
F03 [45566772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
154
1532
—
—
—
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
3.8e-01
5.5e-01
—
—
—
4.5e-01
1.4e-01
cases:20.78%
controls:15.19%
cases:11.69%
controls:7.08%
—
—
—
—
—
—
cases:9.40%
controls:6.17%
cases:21.31%
controls:19.06%
32
234
122
1306
18
109
136
1431
—
—
—
14
92
135
1398
26
232
96
985
Trochanteric bursitis
M70.6 [45606304]
M70.6 [45606304]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
0
6
154
1534
—
—
—
0
10
149
1480
—
Needle biopsy of prostate
TKE00 [2001306182]
TKE00 [2001306182]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
154
1532
—
—
—
—
—
—
temazepam; oral
N05CD07 [21604642]
N05CD07 [21604642]
-1.7e-02
—
—
—
—
—
—
cases:3.90%
controls:3.96%
—
—
—
—
—
—
—
—
—
—
—
—
6
61
148
1479
—
—
—
—
—
—
Spread to lymph node
OMOP4998263 [36768587]
OMOP4998263 [36768587]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
149
1485
—
methotrexate; oral, parenteral
L04AX03 [21603929]
L04AX03 [21603929]
1.1e+00
1.1e+00
—
—
—
9.0e-01
—
cases:5.84%
controls:1.95%
cases:4.55%
controls:1.62%
—
—
—
—
—
—
cases:4.03%
controls:1.68%
—
—
9
30
145
1510
7
25
147
1515
—
—
—
6
25
143
1465
—
General and Unspecified, Medication/prescr/renewal
A50 [2002000184]
A50 [2002000184]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
122
1210
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
8.2e-01
—
—
—
—
-1.0e+50
1.8e-01
cases:3.90%
controls:1.75%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
cases:4.10%
controls:3.45%
6
27
148
1513
—
—
—
—
0
13
149
1477
5
42
117
1175
Standard dental crown
SPC10 [2001310513]
SPC10 [2001310513]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
pravastatin; oral
C10AA03 [21601858]
C10AA03 [21601858]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
0
12
154
1528
—
—
—
0
12
149
1478
—
letrozole; oral
L02BG04 [21603842]
L02BG04 [21603842]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
0
10
154
1530
0
8
154
1532
—
—
—
0
6
149
1484
—
Diverticulum of oesophagus
Q39.6 [45572964]
Q39.6 [45572964]
—
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:57.79%
controls:0.00%
cases:8.44%
controls:0.00%
cases:20.13%
controls:0.00%
cases:17.21%
controls:0.00%
—
—
—
89
0
65
1540
13
0
141
1537
30
0
119
1490
21
0
101
1217
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
-2.2e-01
-6.0e-02
-1.0e+50
—
—
-1.9e-01
4.1e-02
cases:9.74%
controls:11.88%
cases:3.25%
controls:3.44%
cases:0.00%
controls:0.58%
—
—
—
—
cases:3.36%
controls:4.03%
cases:10.66%
controls:10.27%
15
183
139
1357
5
53
149
1487
0
9
154
1531
—
—
5
60
144
1430
13
125
109
1092
Precision impression for denture
SPA47 [2001310477]
SPA47 [2001310477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
hydrochlorothiazide; oral
C03AA03 [21601466]
C03AA03 [21601466]
8.4e-01
—
-1.0e+50
—
—
—
—
cases:5.84%
controls:2.60%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
9
40
145
1500
—
0
5
154
1535
—
—
—
—
Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]
SPAT1292 [2001700393]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
0
5
154
1535
—
—
—
—
0
14
122
1203
Spirometry at the office
SPAT1059 [2001700160]
SPAT1059 [2001700160]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
9
154
1531
—
—
—
—
—
0
8
122
1209
Cervical spine X-ray examination without contrast
NA1AA [2001306981]
NA1AA [2001306981]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Ulcerative colitis, unspecified
K51.9 [45605941]
K51.9 [45605941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
General and Unspecified, Result test/procedure
A60 [2002000194]
A60 [2002000194]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Geriatric Psychiatry
27 [38004470]
27 [38004470]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
donepezil; oral
N06DA02 [21604795]
N06DA02 [21604795]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
0
16
154
1524
0
9
154
1531
—
—
—
0
10
149
1480
—
Structured assessment of psychoactive substance / tobacco use
SPAT1273 [2001700374]
SPAT1273 [2001700374]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Alzheimer disease, unspecified
G30.9 [45591165]
G30.9 [45591165]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
C01DA14 [21600324]
-5.5e-01
—
-1.0e+50
—
—
3.5e-02
4.7e-01
cases:3.25%
controls:5.52%
—
—
cases:0.00%
controls:0.97%
—
—
—
—
cases:4.03%
controls:3.89%
cases:9.02%
controls:5.83%
5
85
149
1455
—
0
15
154
1525
—
—
6
58
143
1432
11
71
111
1146
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
-1.0e-01
1.1e-01
-1.0e+50
—
—
—
-3.5e-01
cases:5.84%
controls:6.43%
cases:3.25%
controls:2.92%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:4.92%
controls:6.82%
9
99
145
1441
5
45
149
1495
0
7
154
1533
—
—
—
6
83
116
1134
Fracture of upper end of tibia
S82.1 [45579358]
S82.1 [45579358]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
D01AE20 [21601959]
—
-1.0e+50
—
—
—
—
6.7e-01
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:4.10%
controls:2.14%
—
0
12
154
1528
—
—
—
—
5
26
117
1191
Cystostatic therapy of methastized malignancy
WD105 [2001310678]
WD105 [2001310678]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
6
154
1534
—
—
—
—
—
Anoscopy
UJH02 [2001305182]
UJH02 [2001305182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Basal cell carcinoma, NOS, of skin, NOS
8090/3-C44.9 [44505057]
8090/3-C44.9 [44505057]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
5
149
1485
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
4.1e-01
8.4e-01
1.1e+00
—
—
7.1e-01
3.2e-01
cases:15.58%
controls:10.91%
cases:13.64%
controls:6.36%
cases:3.90%
controls:1.30%
—
—
—
—
cases:12.08%
controls:6.31%
cases:16.39%
controls:12.49%
24
168
130
1372
21
98
133
1442
6
20
148
1520
—
—
18
94
131
1396
20
152
102
1065
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
E87.1 [45542779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Stroke/cerebrovascular accident
K90 [2002000617]
K90 [2002000617]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Calcium.ionized [Moles/volume] in Venous blood
41645-3 [3033705]
41645-3 [3033705]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
0
6
154
1534
—
—
—
—
—
0
13
122
1204
Other hypothyroidism
E03 [45581337]
E03 [45581337]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
8
154
1532
0
7
154
1533
—
—
—
—
—
Demanding periodontal treatment
SDA04 [2001310329]
SDA04 [2001310329]
7.2e-01
6.3e-01
—
—
—
—
4.6e-01
cases:8.44%
controls:4.29%
cases:3.25%
controls:1.75%
—
—
—
—
—
—
—
—
cases:8.20%
controls:5.34%
13
66
141
1474
5
27
149
1513
—
—
—
—
10
65
112
1152
doxepin; oral, parenteral
N06AA12 [21604699]
N06AA12 [21604699]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
Melanocytic naevi, unspecified
D22.9 [45571603]
D22.9 [45571603]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
8
154
1532
0
5
154
1535
—
—
—
—
0
6
122
1211
Application of soft bandage
SPAT1211 [2001700312]
SPAT1211 [2001700312]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
Prick test
37968009 [4242723]
37968009 [4242723]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction
60022-1 [40763082]
60022-1 [40763082]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Hypersensitivity skin testing
268377001 [4147813]
268377001 [4147813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Diabetes insulin dependent
T89 [2002001130]
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:1.07%
0
15
154
1525
0
7
154
1533
—
—
—
0
10
149
1480
0
13
122
1204
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
3.9e-01
—
—
—
—
—
—
cases:3.90%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
—
—
6
41
148
1499
—
—
—
—
—
—
Faecal incontinence
R15 [45573014]
R15 [45573014]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
SPAT1256 [2001700357]
2.0e-01
—
—
—
—
4.8e-01
-2.1e-01
cases:11.04%
controls:9.22%
—
—
—
—
—
—
—
—
cases:6.04%
controls:3.83%
cases:6.56%
controls:7.97%
17
142
137
1398
—
—
—
—
9
57
140
1433
8
97
114
1120
Pleural plaque with presence of asbestos
J92.0 [45567277]
J92.0 [45567277]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Migraine
G43 [45566873]
G43 [45566873]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
5
154
1535
—
—
—
—
—
0
6
122
1211
Other function in accordance with physical therapy nomenclature
SPAT1295 [2001700396]
SPAT1295 [2001700396]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
Fat metabolism disorder associated with chronic coronary artery disease
213 [2001600209]
213 [2001600209]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
154
1521
—
—
—
—
—
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
22748-8 [3001308]
2.2e-01
4.2e-01
—
—
—
-3.1e-02
-4.8e-02
cases:37.01%
controls:31.95%
cases:28.57%
controls:20.84%
—
—
—
—
—
—
cases:22.15%
controls:22.68%
cases:42.62%
controls:43.80%
57
492
97
1048
44
321
110
1219
—
—
—
33
338
116
1152
52
533
70
684
Erythropoietin (EPO) [Units/volume] in Serum or Plasma
15061-5 [3024172]
15061-5 [3024172]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Benign neoplasm: Adrenal gland
D35.0 [45576391]
D35.0 [45576391]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
3879-4 [3027008]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Ingrowing nail
L60.0 [45548199]
L60.0 [45548199]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
122
1211
Chronic gingivitis
K05.18 [2000502721]
K05.18 [2000502721]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Laceration/cut
S18 [2002000983]
S18 [2002000983]
2.0e-01
2.0e-01
—
—
—
3.9e-01
3.7e-01
cases:10.39%
controls:8.64%
cases:3.25%
controls:2.66%
—
—
—
—
—
—
cases:4.70%
controls:3.22%
cases:13.93%
controls:10.02%
16
133
138
1407
5
41
149
1499
—
—
—
7
48
142
1442
17
122
105
1095
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
31843-6 [3013139]
1.1e+00
—
—
—
—
—
-1.0e+50
cases:3.90%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
6
20
148
1520
—
—
—
—
—
0
11
122
1206
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
SPAT1028 [2001700129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
Cervicobrachial syndrome
M53.1 [45567577]
M53.1 [45567577]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
CK2X4 [2001301456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
12
154
1528
—
—
—
—
—
Plugged feeling ear
H13 [2002000480]
H13 [2002000480]
—
—
—
—
—
—
-2.3e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.10%
controls:4.19%
—
—
—
—
—
—
5
51
117
1166
Presence of coronary angioplasty implant and graft
Z95.5 [45542496]
Z95.5 [45542496]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
22126-7 [3010380]
22126-7 [3010380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
154
1535
—
—
—
—
—
—
Breast cancer
115 [2001600115]
115 [2001600115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Infiltrating duct carcinoma, NOS, of breast, NOS
8500/3-C50.9 [44505315]
8500/3-C50.9 [44505315]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Other function in accordance with podiatry nomenclature
SPAT1299 [2001700400]
SPAT1299 [2001700400]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
122
1212
fluticasone furoate
R03BA09 [45893496]
R03BA09 [45893496]
7.2e-01
1.5e+00
—
—
—
—
3.2e-01
cases:4.55%
controls:2.27%
cases:5.19%
controls:1.17%
—
—
—
—
—
—
—
—
cases:4.92%
controls:3.62%
7
35
147
1505
8
18
146
1522
—
—
—
—
6
44
116
1173
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
2.3e-01
—
—
—
—
—
3.2e-01
cases:7.79%
controls:6.30%
—
—
—
—
—
—
—
—
—
—
cases:8.20%
controls:6.08%
12
97
142
1443
—
—
—
—
—
10
74
112
1143
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
2.8e-01
9.4e-01
—
—
—
9.0e-01
1.5e-02
cases:3.25%
controls:2.47%
cases:3.90%
controls:1.56%
—
—
—
—
—
—
cases:4.03%
controls:1.68%
cases:4.92%
controls:4.85%
5
38
149
1502
6
24
148
1516
—
—
—
6
25
143
1465
6
59
116
1158
terbutaline; oral, parenteral
R03CC03 [21603313]
R03CC03 [21603313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
351 [2001600312]
8.4e-01
—
—
—
—
—
—
cases:4.55%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
7
31
147
1509
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
7.8e-02
—
—
—
—
—
4.5e-01
cases:8.44%
controls:7.86%
—
—
—
—
—
—
—
—
—
—
cases:7.38%
controls:4.85%
13
121
141
1419
—
—
—
—
—
9
59
113
1158
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
22246-3 [3017918]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
154
1533
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
Z87.1 [45542474]
-2.2e-01
8.4e-01
—
—
-1.0e+50
7.0e-01
5.4e-01
cases:9.09%
controls:11.04%
cases:5.84%
controls:2.60%
—
—
—
—
cases:0.00%
controls:0.46%
cases:6.04%
controls:3.09%
cases:10.66%
controls:6.49%
14
170
140
1370
9
40
145
1500
—
—
0
7
154
1530
9
46
140
1444
13
79
109
1138
C reactive protein [Mass/volume] in Capillary blood
48421-2 [3051387]
48421-2 [3051387]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
0
8
154
1532
0
7
154
1533
—
—
—
—
0
13
122
1204
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
3.4e-01
7.8e-01
—
—
-1.0e+50
9.8e-01
4.4e-01
cases:8.44%
controls:6.17%
cases:3.90%
controls:1.82%
—
—
—
—
cases:0.00%
controls:0.46%
cases:4.70%
controls:1.81%
cases:8.20%
controls:5.42%
13
95
141
1445
6
28
148
1512
—
—
0
7
154
1530
7
27
142
1463
10
66
112
1151
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
92
603
2.07
5.44
2.4
2.0
93.36
96.72
pmol/l
0.31
48
311
65
384
2.08
5.00
4.2
2.7
—
—
—
0
0
108
781
1.95
4.54
8.1
9.6
1.21
1.21
mmol/l
0.40
97
688
30
133
2.51
4.53
1.6
1.4
—
—
—
0
0
119
899
1.94
4.29
7.6
11.4
4.52
4.17
e9/l
0.50
98
782
96
686
1.85
4.01
4.3
3.2
—
—
estimate
—
0
0
48
278
1.99
3.78
4.5
3.6
296.80
500.44
ng/l
0.41
40
216
64
411
1.86
3.69
1.7
1.6
20.98
20.80
nmol/l
0.03
53
347
14
47
3.14
3.49
4.3
3.4
2.71
3.34
index
—
7
30
70
470
1.80
3.46
2.9
3.4
0.24
0.38
e6/l
0.69
53
338
117
917
1.78
3.35
7.6
6.7
6.29
6.80
mmol/l
2.34
111
874
55
356
1.78
3.02
2.6
3.5
341.21
350.64
umol/l
0.32
48
316
62
421
1.72
2.86
2.7
2.5
2.74
2.85
mg/l
0.13
56
373
102
792
1.66
2.82
7.1
7.4
13.74
13.03
umol/l
0.16
97
759
95
730
1.63
2.69
8.9
9.0
1.21
1.21
mmol/l
0.06
90
682
64
465
1.58
2.18
3.1
3.5
684.52
1593.43
ng/l
4.04
59
390
77
584
1.55
2.18
3.2
3.8
—
—
—
0
0
43
286
1.66
2.09
2.5
2.9
2.47
2.47
mmol/l
0.08
38
252
41
270
1.67
2.06
2.8
3.1
1.49
2.57
e6/l
0.51
21
133
83
650
1.51
1.99
2.5
2.7
76.70
75.40
nmol/l
0.13
76
588
8
28
2.94
1.88
1.3
1.3
—
—
—
0
0
141
1246
1.60
1.84
23.7
16.6
82.49
81.61
ml/min/173m2
0.20
134
1140
6
20
3.07
1.59
2.5
2.6
1.33
0.75
index
—
6
20
157
1439
1.69
1.59
25.5
17.6
26.64
25.02
mg/l
0.31
143
1173
13
64
2.11
1.58
1.5
2.0
31.77
39.48
u/l
0.96
13
56
41
292
1.52
1.49
2.3
3.0
0.52
0.84
e6/l
0.73
21
153
9
38
2.44
1.48
2.0
1.2
—
—
—
0
0
5
16
3.18
1.45
1.4
1.3
—
—
—
0
0
37
260
1.53
1.42
2.0
1.9
—
—
—
0
0
11
53
2.15
1.41
1.9
2.9
—
—
—
0
0
110
949
1.41
1.41
3.5
3.8
49.57
50.68
u/l
0.05
104
905
29
193
1.60
1.40
2.0
1.9
—
—
—
0
0
38
271
1.51
1.37
1.8
2.9
29.24
29.64
s
0.23
38
264
29
195
1.58
1.35
2.1
1.8
—
—
—
0
0
11
55
2.06
1.30
2.5
3.2
1215.55
633.41
u/ml
0.18
11
46
8
36
2.28
1.26
1.3
1.3
—
—
—
0
0
8
36
2.28
1.26
1.3
1.3
—
—
—
0
0
5
19
2.68
1.22
1.6
1.2
—
—
—
0
0
57
450
1.39
1.20
2.5
2.2
192.49
241.04
u/l
0.29
57
436
5
20
2.54
1.16
1.0
1.2
—
—
—
0
0
7
31
2.31
1.11
1.3
1.5
—
—
—
0
0
9
161
0.54
1.03
1.0
1.9
—
—
—
0
0
165
1566
1.61
1.01
34.1
26.1
254.70
249.81
e9/l
0.41
160
1538
165
1566
1.61
1.01
34.0
26.0
4.43
4.51
e12/l
1.00
160
1533
25
175
1.50
0.99
8.3
6.6
1.24
1.54
mmol/l
0.18
18
130
41
316
1.38
0.99
2.0
2.4
1.24
1.60
mg/l
0.47
31
267
8
42
1.95
0.90
1.0
1.6
—
—
—
0
0
8
44
1.86
0.87
1.8
2.6
25.04
33.71
mg/l
—
8
37
8
44
1.86
0.87
1.8
2.6
29.15
179.04
mg/l
—
8
37
8
45
1.81
0.85
1.4
1.4
—
—
—
0
0
20
139
1.49
0.83
3.0
3.4
0.09
0.17
e6/l
0.73
20
134
106
953
1.27
0.83
3.5
3.3
—
—
—
0
0
29
218
1.39
0.82
1.3
1.3
162.91
7.43
u/ml
0.51
11
87
15
100
1.55
0.75
2.1
6.4
1.23
1.23
%
0.01
15
100
32
251
1.33
0.70
1.5
1.3
42.37
25.81
iu/ml
0.27
11
75
37
453
0.77
0.69
2.6
4.3
0.00
0.00
estimate
—
10
154
14
94
1.53
0.69
1.4
1.7
—
—
—
0
0
5
28
1.81
0.66
3.6
3.1
304.80
191.30
e6/l
—
5
20
10
153
0.63
0.66
4.6
8.1
—
—
—
0
0
12
176
0.66
0.66
1.1
2.1
—
—
—
0
0
5
29
1.74
0.64
1.4
11.2
—
4176.67
—
0
6
156
1491
1.34
0.63
13.4
12.1
24.47
26.41
u/l
0.66
151
1458
31
247
1.31
0.62
1.5
1.7
914.81
1260.83
nmol/l
1.83
22
198
5
30
1.69
0.62
1.0
1.4
—
—
—
0
0
14
97
1.48
0.61
2.1
6.5
0.64
0.62
%
0.03
14
97
0
22
0.00
0.59
0.0
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.4
—
—
—
0
0
12
81
1.52
0.58
3.3
14.1
0.98
1.28
mg/l
1.71
12
75
117
1089
1.21
0.56
5.5
4.4
13.04
11.52
mm/h
0.60
110
1023
9
59
1.55
0.56
1.0
1.3
—
—
—
0
0
20
152
1.36
0.55
3.6
8.1
22.87
23.78
mmol/l
0.69
20
152
9
62
1.47
0.54
1.3
1.6
—
—
—
0
0
9
62
1.47
0.54
1.3
1.5
—
—
—
0
0
51
584
0.82
0.53
3.8
4.2
0.22
0.00
estimate
—
9
140
7
49
1.45
0.46
1.0
1.3
—
—
—
0
0
7
49
1.45
0.46
1.7
2.2
—
—
—
0
0
7
51
1.39
0.44
1.0
1.3
—
2.61
—
0
9
35
297
1.22
0.44
2.9
3.2
0.80
0.77
ug/l
0.06
26
199
5
33
1.53
0.41
1.2
1.3
—
—
—
0
0
33
281
1.21
0.40
1.6
1.9
467.65
465.35
pmol/l
0.01
26
237
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.5
—
—
—
0
0
5
36
1.40
0.38
1.4
1.3
—
—
—
0
0
24
199
1.24
0.37
2.7
6.8
4.90
4.79
kpa
0.12
24
193
130
1245
1.16
0.35
3.9
4.3
1.13
1.26
mmol/l
2.28
121
1150
6
46
1.31
0.33
1.3
1.5
0.00
0.00
g/l
—
6
41
6
46
1.31
0.33
1.2
1.7
—
—
—
0
0
41
459
0.86
0.32
3.5
4.2
3.70
10.60
mg/mmol
2.90
31
310
7
99
0.70
0.31
1.0
1.1
—
—
—
0
0
7
52
1.36
0.31
1.1
1.6
—
—
—
0
0
15
121
1.26
0.29
2.1
1.8
—
—
—
0
0
22
187
1.20
0.28
2.7
4.1
7.50
10.39
umol/l
0.39
22
161
5
41
1.23
0.22
1.2
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
3.7
—
—
—
0
0
0
11
0.00
0.21
0.0
3.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
1009.20
—
0
10
0
12
0.00
0.21
0.0
1.0
—
218.08
—
0
12
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
662.00
—
0
7
0
12
0.00
0.21
0.0
1.0
—
32.00
—
0
6
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
84
800
1.09
0.21
3.3
4.1
137.09
0.00
estimate
0.47
11
166
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
11
90
1.24
0.19
2.9
1.4
—
—
—
0
0
6
51
1.18
0.19
1.8
2.0
—
—
—
0
0
13
152
0.84
0.17
1.2
1.3
—
—
—
0
0
5
67
0.74
0.17
3.4
5.8
75.20
89.24
%
—
5
67
55
523
1.07
0.13
6.2
5.6
2.65
2.04
ug/l
0.50
50
464
125
1277
0.93
0.13
5.8
6.5
37.33
39.58
mmol/mol
3.86
119
1205
82
794
1.06
0.11
3.2
4.1
0.00
0.00
estimate
—
10
169
5
44
1.14
0.10
2.0
1.4
—
121.26
—
0
16
43
410
1.06
0.09
3.7
3.8
0.22
0.00
estimate
—
9
136
5
47
1.07
0.09
1.2
1.2
—
—
—
0
0
5
48
1.04
0.09
1.2
1.2
—
—
—
0
0
130
1319
0.95
0.08
4.8
5.0
4.32
4.46
mmol/l
1.03
121
1232
24
225
1.08
0.08
3.3
7.0
5.49
5.77
kpa
1.29
24
218
6
73
0.82
0.08
2.2
1.3
—
—
—
0
0
135
1334
1.05
0.06
5.6
5.6
2.50
2.62
mmol/l
1.08
125
1245
17
182
0.93
0.06
1.8
2.5
397.00
385.04
nmol/l
0.08
17
170
82
804
1.04
0.06
3.4
4.2
0.00
0.03
estimate
—
10
152
113
1116
1.03
0.05
3.7
4.1
14.87
14.81
pmol/l
0.08
108
1023
130
1313
0.96
0.04
4.9
5.1
1.90
1.95
mu/l
0.15
123
1212
18
170
1.07
0.04
2.4
1.6
1.50
1.52
%
0.06
18
144
130
1311
0.97
0.03
4.7
4.8
1.42
1.41
mmol/l
0.15
121
1217
128
1288
0.98
0.01
5.0
5.0
5.78
5.96
mmol/l
1.50
118
1193
36
354
1.02
0.00
3.8
4.3
1.02
1.02
kg/l
0.00
24
230
41
414
0.99
0.00
5.3
4.7
23.02
21.82
%
0.22
22
213
31
309
1.00
0.00
1.5
1.9
—
—
—
0
0
55
551
1.00
0.00
2.1
2.1
1.29
1.32
mmol/l
0.16
48
469
58
577
1.01
0.00
4.8
4.1
27.44
47.53
ng/l
1.27
38
435
16
158
1.01
0.00
4.1
3.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
7.23
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
5.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
67.00
—
0
7
6
65
0.92
-0.00
1.0
1.5
1.48
1.18
g/l
—
6
65
0
7
0.00
-0.00
0.0
1.0
—
0.21
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
0.31
—
0
7
0
9
0.00
-0.00
0.0
4.8
—
103.78
—
0
9
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
0.03
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
-0.00
1.0
1.5
0.30
0.24
g/l
—
6
65
0
6
0.00
-0.00
0.0
5.0
—
26.67
—
0
6
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
170.14
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.7
—
23.65
—
0
6
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint Q17_CONGEN_MALFO_OESOPHAGUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| Q17_CONGEN_MALFO_OESOPHAGUS | 1.319 [0.99, 1.76] | 0.062 |
| Birth year | 0.992 [0.98, 1.0] | 0.098 |
During the follow-up period (1.1.1998 — 31.12.2019), 92 out of 492 females with Q17_CONGEN_MALFO_OESOPHAGUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| Q17_CONGEN_MALFO_OESOPHAGUS | 1.592 [1.12, 2.26] | 0.009 |
| Birth year | 0.988 [0.98, 1.0] | 0.033 |
During the follow-up period (1.1.1998 — 31.12.2019), 92 out of 579 males with Q17_CONGEN_MALFO_OESOPHAGUS died.
Mortality risk
Mortality risk for people of age
years, who have Q17_CONGEN_MALFO_OESOPHAGUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.147% | 0.364% |
| 5 | 0.706% | 2.122% |
| 10 | 1.784% | 5.113% |
| 15 | 3.469% | 8.932% |
| 20 | 6.047% | 14.384% |
Relationships between endpoints
↥Index endpoint: Q17_CONGEN_MALFO_OESOPHAGUS – Congenital malformations of oesophagus
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data